In line with a hypoxia-mediated increase in invasiveness following anti-angiogenic therapy, we found that HIF-1α was highly upregulated directly behind the invasive front in bevacizumab-treated gliomas (Fig. 6a). The gene discussed is HIF1A; the disease is glioma.